IPO-2

 

Hosted by      Kempen-Logo_high-resolution-1-1

IPO OF THE YEAR

 
This award recognises a company that has successfully completed a significant, impactful or transformational IPO on any international exchange.
 
It is open to European life science companies only.

Qualifying criteria

- Must be a public company
- Must have raised the funds in the period between 1 September 2018 to 1 September 2019
- Must be a company with a European headquarters
- Raise must be an IPO NOT a secondary placement or follow-on 

Judges will be paying particular attention to:

- Amount of funds raised
- Process / speed / allocation fulfilment of securing of significant new funds
- Level / reputation of new investor(s) attracted
- Post-finance allocation / use of proceeds
- Level of value creation / value realisation from raise
 
 
 

2019 WINNER

 

Genmab-01-1

 

 

(L-R) Ellie Taylor, Emcee, Anthony Pagano, Senior Vice President, Finance and Corporate Development, Genmab, Andrew Carlsen, Senior Director, IR, Genmab and Jan de Kerpel, Managing Director, Kempen.

 

2019 HIGHLY COMMENDED

 

Bicycle .         Uniphar-01-1
 
 
 

ALL 2019 FINALISTS

 

Ascelia Pharma

ASCELIA PHARMA, SWEDEN

Bicycle Therapeutics

BICYCLE THERAPEUTICS, UNITED KINGDOM

Genmab

GENMAB, DENMARK

Hookipa Pharma

HOOKIPA PHARMA, AUSTRIA

Sequana Medical

SEQUANA MEDICAL, BELGIUM

Uniphar

UNIPHAR, IRELAND

BUY TICKETS AND TABLES